Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies

被引:13
|
作者
Frelau, Alexandra [1 ]
Palard-Novello, Xavier [2 ]
Jali, Eva [3 ]
Boussemart, Lise [4 ]
Dupuy, Alain [4 ]
James, Pandora [5 ]
Devillers, Anne [2 ]
Le Jeune, Florence [2 ]
Edeline, Julien [1 ]
Lesimple, Thierry [1 ]
Girard, Antoine [2 ]
机构
[1] Eugene Marquis Ctr, Dept Oncol, Rennes, France
[2] Eugene Marquis Ctr, Dept Nucl Med, Ave La Bataille Flandres Dunkerque, F-35000 Rennes, France
[3] Univ Hosp, Dept Endocrinol, Brest, France
[4] Univ Hosp, Dept Dermatol, Rennes, France
[5] Univ Hosp, Dept Gynecol, Brest, France
关键词
18F-FDG PET; CT; Metastatic melanoma; Anti-PD-1; antibodies; Thyroid; Immune-related adverse events; Immune checkpoint inhibitors; ADVERSE EVENTS; METASTATIC MELANOMA; CLINICAL-RESPONSE; NIVOLUMAB; IPILIMUMAB; F-18-FLUORODEOXYGLUCOSE; IMMUNOTHERAPY; PEMBROLIZUMAB; INHIBITORS; ANTIGEN-4;
D O I
10.1007/s00262-020-02712-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To determine performances of 2-deoxy-2-(18F)fluoro-d-glucose (18F-FDG) positron emission tomography (PET) to detect the development of permanent thyroid dysfunction (PTD), and to evaluate the prognostic value of early increased thyroid uptake in stage IV melanoma patients treated with anti-programmed death 1 (anti-PD-1) antibodies. Methods Twenty-nine patients were retrospectively enrolled. PTD was defined as symptomatic thyroid disorder requiring long-term specific treatment. On the first PET performed during follow-up, maximal standardized uptake value of the thyroid (SUVmax-Th) and SUVmax-Th/SUVmax-blood-pool ratio (Th/B) were measured. Areas under ROC curves (AUC) of these parameters for the diagnostic of PTD were compared. Cutoff values were defined to maximize the Youden's index. Survival analyses were performed according to the Kaplan-Meier method and compared using the log-rank method between patients with and without enhanced thyroid uptake according to cutoff values defined with the Hothorn and Lausen method. Results Four patients presented PTD. Median SUVmax-Th and Th/B were, respectively, 2.11 and 1.00. The median follow-up period was 21.7 months. AUC were 1.0 (CI(95%)0.88-1.0) for both parameters. Optimal cutoff values were, respectively, SUVmax-Th > 4.1 and Th/B > 2.0, both conferring sensitivities of 100% (CI(95%)40-100%) and specificities of 100% (CI(95%)86-100%). The median progression-free survival and overall survival were 11.3 months and 33.5 months, respectively. Using optimized cutoffs, there was no statistically significant difference of survival. Conclusion SUVmax-Th > 4.1 and Th/B > 2.0 provided perfect diagnostic performances to detect patients that developed PTD. No significant survival difference was found between patients with and without increased thyroid uptake.
引用
收藏
页码:679 / 687
页数:9
相关论文
共 41 条
  • [1] Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies
    Alexandra Frelau
    Xavier Palard-Novello
    Eva Jali
    Lise Boussemart
    Alain Dupuy
    Pandora James
    Anne Devillers
    Florence Le Jeune
    Julien Edeline
    Thierry Lesimple
    Antoine Girard
    Cancer Immunology, Immunotherapy, 2021, 70 : 679 - 687
  • [2] Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
    Sachpekidis, Christos
    Kopp-Schneider, Annette
    Pan, Leyun
    Papamichail, Dimitrios
    Haberkorn, Uwe
    Hassel, Jessica C.
    Dimitrakopoulou-Strauss, Antonia
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (06) : 1932 - 1943
  • [3] Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
    Sachpekidis, Christos
    Hassel, Jessica C.
    Kopp-Schneider, Annette
    Haberkorn, Uwe
    Dimitrakopoulou-Strauss, Antonia
    CANCERS, 2021, 13 (05) : 1 - 17
  • [4] Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies
    Frelau, Alexandra
    Jali, Eva
    Campillo-Gimenez, Boris
    Pracht, Marc
    Porneuf, Marc
    Dinulescu, Monica
    Edeline, Julien
    Boussemart, Lise
    Lesimple, Thierry
    MELANOMA RESEARCH, 2021, 31 (03) : 208 - 217
  • [5] Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma
    Schuele, Susann-Cathrin
    Eigentler, Thomas Kurt
    Garbe, Claus
    la Fougere, Christian
    Nikolaou, Konstantin
    Pfannenberg, Christina
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (03) : 482 - 488
  • [6] Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Nakamoto, Ryusuke
    Zaba, Lisa C.
    Liang, Tie
    Reddy, Sunil Arani
    Davidzon, Guido
    Aparici, Carina Mari
    Nguyen, Judy
    Moradi, Farshad
    Iagaru, Andrei
    Franc, Benjamin Lewis
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) : 1380 - 1383
  • [7] Prognostic and predictive interest of 18F-FDG PET/CT in the initial assessment of stage IIIB-C-D and IV patients with melanoma before anti-PD-1 immunotherapy
    Sebille, J-C
    Eugene, T.
    Carlier, T.
    Kraeber-Bodere, F.
    Bailly, C.
    Khammari, A.
    Dreno, B.
    Bodet-Milin, C.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2020, 44 (01): : 65 - 71
  • [8] Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
    Christos Sachpekidis
    Annette Kopp-Schneider
    Leyun Pan
    Dimitrios Papamichail
    Uwe Haberkorn
    Jessica C. Hassel
    Antonia Dimitrakopoulou-Strauss
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1932 - 1943
  • [9] 18F-FDG PET/CT of Multiorgan Sarcoid-Like Reaction During Anti-PD-1 Treatment for Melanoma
    van Willigen, Wouter W.
    Gerritsen, Winald R.
    Aarntzen, Erik H. J. G.
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (11) : 905 - 906
  • [10] Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
    Seban, Romain-David
    Nemer, John S.
    Marabelle, Aurelien
    Yeh, Randy
    Deutsch, Eric
    Ammari, Samy
    Moya-Plana, Antoine
    Mokrane, Fatima-Zohra
    Gartrell, Robyn D.
    Finkel, Grace
    Barker, Luke
    Bigorgne, Amelie E.
    Schwartz, Lawrence H.
    Saenger, Yvonne
    Robert, Caroline
    Dercle, Laurent
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (11) : 2298 - 2310